Straightforward and Productive Methods for Synthesis of Efficacious Tlr2 Agonistic Lipopeptides

Vaccination is the most competent armament against the barrage of microorganisms. The whole organism vaccines are sporadically inimical to the host because of its secondary constituents such as endotoxins which may induce toxic shock symptoms. Modern Vaccines are bacterial polysaccharides or viral surface proteins which are capable of inducing an immune response in isolation from the attenuated pathogen itself, but the major downside to these relatively modern vaccines is their intrinsic inability to furnish the expected immune response by themselves. Stimulation of the innate immune system by agonists holds the key to the success of recombinant subunit vaccines. The toll-like receptors are pattern recognizing receptors (PRRs) which play an important role in our immunity, and their timely activation by using their corresponding agonists can promote a vigorous immune response to otherwise less immunogenic modern subunit vaccines. TLRs can be rendered active without the presence of the pathogen, provided the specific ligands of the pathogen associated with inducing the immune response is introduced to these receptors. These specific ligands are called agonists, and their utility in the world of vaccination is profound. TLR2 has a special place among the 10 members of the human TLR family because this receptor is capable of detecting the largest repertoire of Pathogen associated molecular patterns (PAMPs) from a large variety of pathogens, including gram-positive or gram-negative bacteria, mycobacteria, fungi, viruses, and parasites. Bacterial lipoproteins are considered the most potent naturally occurring agonists recognized by TLR2. It is the need of the hour to take a proactive approach to develop more immunomodulatory molecules for clinical trials. We are striving towards devising simple and straightforward methods for the synthesis of TLR2 agonistic lipopeptides.